Roivant Highlights IMVT-1402 for 85,000 Difficult-to-Treat RA Patients

Your call?🐂 Bullish🐻 Bearish

Roivant estimates 85,000 people have difficult-to-treat RA. At Week 28, 92.5% of the 600-milligram group maintained an ACR20 response, compared with about 75% on placebo.